全文获取类型
收费全文 | 115558篇 |
免费 | 10120篇 |
国内免费 | 3210篇 |
专业分类
耳鼻咽喉 | 1022篇 |
儿科学 | 1774篇 |
妇产科学 | 1465篇 |
基础医学 | 9704篇 |
口腔科学 | 2405篇 |
临床医学 | 16103篇 |
内科学 | 11522篇 |
皮肤病学 | 1055篇 |
神经病学 | 10943篇 |
特种医学 | 3349篇 |
外国民族医学 | 7篇 |
外科学 | 8672篇 |
综合类 | 16972篇 |
现状与发展 | 7篇 |
一般理论 | 3篇 |
预防医学 | 18827篇 |
眼科学 | 1406篇 |
药学 | 11784篇 |
301篇 | |
中国医学 | 6580篇 |
肿瘤学 | 4987篇 |
出版年
2024年 | 236篇 |
2023年 | 2232篇 |
2022年 | 2854篇 |
2021年 | 5182篇 |
2020年 | 5364篇 |
2019年 | 4323篇 |
2018年 | 4079篇 |
2017年 | 4362篇 |
2016年 | 4492篇 |
2015年 | 4381篇 |
2014年 | 8271篇 |
2013年 | 8882篇 |
2012年 | 7574篇 |
2011年 | 7864篇 |
2010年 | 6141篇 |
2009年 | 5925篇 |
2008年 | 6018篇 |
2007年 | 5662篇 |
2006年 | 5124篇 |
2005年 | 4236篇 |
2004年 | 3499篇 |
2003年 | 3003篇 |
2002年 | 2350篇 |
2001年 | 2008篇 |
2000年 | 1625篇 |
1999年 | 1349篇 |
1998年 | 1227篇 |
1997年 | 1175篇 |
1996年 | 864篇 |
1995年 | 925篇 |
1994年 | 854篇 |
1993年 | 738篇 |
1992年 | 682篇 |
1991年 | 603篇 |
1990年 | 495篇 |
1989年 | 440篇 |
1988年 | 435篇 |
1987年 | 410篇 |
1986年 | 361篇 |
1985年 | 496篇 |
1984年 | 425篇 |
1983年 | 255篇 |
1982年 | 282篇 |
1981年 | 261篇 |
1980年 | 234篇 |
1979年 | 153篇 |
1978年 | 138篇 |
1977年 | 121篇 |
1976年 | 88篇 |
1974年 | 46篇 |
排序方式: 共有10000条查询结果,搜索用时 812 毫秒
91.
目的 应用锥形束CT(cone beam CT,CBCT)测量种植区牙槽骨质量并结合Lekholm和Zarb分类法对骨质量分类方法进行改良,以期为提高牙槽骨质量分类的准确性提供指导。方法 选择2015年10月至2017年10月在呼和浩特市口腔医院种植科进行种植修复的196例患者术前CBCT影像资料,应用 Invivo5诊断设计软件测量306个种植位点的牙槽骨皮质骨厚度和松质骨密度(皮质骨与松质骨的CT值差值),以Lekholm和Zarb分类法为基础结合测量数据对骨质量进行改良后的量化分类。结果 牙槽骨皮质骨厚度为0.18 ~ 2.89 mm,中位数为0.92 mm。皮质骨与松质骨的CT值差值为88.5 ~ 667.8 HU,应用百分位数法找到33.3%和66.6%对应的数值分别为297.8 HU和356.1 HU。依据此数据结合Lekholm和Zarb分类法将196例患者的306个种植位点骨质量分为4类,其中Ⅰ类骨种植位点46个(占15.0%),Ⅱ类骨104个(占34.0%),Ⅲ类骨114个(占37.3%),Ⅳ类骨42个(占13.7%)。结论 结合Lekholm和Zarb分类法,应用CBCT测量种植区牙槽骨质量并进行分类方法的改良,可为临床医生术前评估牙槽骨质量提供一定参考。 相似文献
92.
93.
Eloise R. Galligan Leila H. Shayegan Christine T. Lauren Kimberly D. Morel 《Pediatric dermatology》2019,36(5):753-754
Shaving and other modes of epilation can cause undue anxiety, pain, or skin irritation in children. Here, we present hair trimming as a safe, painless, and cost‐effective alternative for patients with unwanted hair which may be performed indefinitely or until the child is old enough to direct management. In select cases, removing unwanted hair using this technique may facilitate dermatologic surveillance. 相似文献
94.
A developmental validation was performed to demonstrate reliability, reproducibility and robustness of the ANDE System with the FlexPlex assay, including an integrated Expert System, across a number of laboratories and buccal sample variations. Previously, the related DNAscan™/ANDE 4C Rapid DNA System using the PowerPlex®16 assay and integrated Expert System Software received NDIS approval in March 2016. The enhanced ANDE instrument, referred to as ANDE 6C, and the accompanying 6-dye, 27-locus STR assay, referred to as FlexPlex, have been developed to be compatible with all widely used global loci, including the expanded set of the CODIS core 20 loci.Six forensic and research laboratories participated in the FlexPlex Rapid DNA developmental validation experiments, testing a total of 2045 swabs, including those obtained from 1387 unique individuals. The goal of this extensive and comprehensive validation was to thoroughly evaluate and document the ANDE System and its internal Expert System to reliably genotype reference buccal swab samples in a manner compliant with the FBI’s Quality Assurance Standards and the NDIS Operational Procedures.The ANDE System, including automated Expert System analysis, generated reproducible and concordant results for buccal swabs when testing various instruments at different laboratories by a number of different operators. When testing a number of non-human DNAs, including oral bacteria, the ANDE System and FlexPlex assay demonstrated limited cross-reactivity. Potential PCR inhibitors were evaluated as part of the validation and no inhibition was detected. Reproducible and concordant profiles were generated from buccal swab samples collected with a limit of detection appropriate for buccal swab collections from arrestees. The precision and resolution of the System met industry standards for detection of microvariants and single base resolution.The integrated Expert System appropriately demonstrated the ability to correctly pass or fail profiles for CODIS upload without human review. During this comprehensive developmental validation, the ANDE System successfully interpreted over 2000 samples tested with over 99.99% concordant alleles. The data package described herein led to the ANDE System with the FlexPlex assay receiving NDIS approval in June 2018. 相似文献
95.
Mt D. Dbrssy Chockalingam Ramanathan Danesh Ashouri Vajari Yixin Tong Thomas Schlaepfer Volker A. Coenen 《The European journal of neuroscience》2021,53(1):89-113
Deep brain stimulation (DBS) in psychiatric illnesses has been clinically tested over the past 20 years. The clinical application of DBS to the superolateral branch of the medial forebrain bundle in treatment‐resistant depressed patients—one of several targets under investigation—has shown to be promising in a number of uncontrolled open label trials. However, there are remain numerous questions that need to be investigated to understand and optimize the clinical use of DBS in depression, including, for example, the relationship between the symptoms, the biological substrates/projections and the stimulation itself. In the context of precision and customized medicine, the current paper focuses on clinical and experimental research of medial forebrain bundle DBS in depression or in animal models of depression, demonstrating how clinical and scientific progress can work in tandem to test the therapeutic value and investigate the mechanisms of this experimental treatment. As one of the hypotheses is that depression engenders changes in the reward and motivational networks, the review looks at how stimulation of the medial forebrain bundle impacts the dopaminergic system. 相似文献
96.
《Journal of pharmaceutical sciences》2019,108(11):3521-3523
We make the case for why continuous pharmaceutical manufacturing is essential, what the barriers are, and how to overcome them. To overcome them, government action is needed in terms of tax incentives or regulatory incentives that affect time. 相似文献
97.
《Saudi Pharmaceutical Journal》2022,30(6):669-678
BackgroundIschemia reperfusion (I/R) play an imperative role in the expansion of cardiovascular disease. Sinomenine (SM) has been exhibited to possess antioxidant, anticancer, anti-inflammatory, antiviral and anticarcinogenic properties. The aim of the study was scrutinized the cardioprotective effect of SM against I/R injury in rat.MethodsRat were randomly divided into normal control (NC), I/R control and I/R + SM (5, 10 and 20 mg/kg), respectively. Ventricular arrhythmias, body weight and heart weight were estimated. Antioxidant, inflammatory cytokines, inflammatory mediators and plasmin system indicator were accessed.ResultsPre-treated SM group rats exhibited the reduction in the duration and incidence of ventricular fibrillation, ventricular ectopic beat (VEB) and ventricular tachycardia along with suppression of arrhythmia score during the ischemia (30 and 120 min). SM treated rats significantly (P < 0.001) altered the level of antioxidant parameters. SM treatment significantly (P < 0.001) repressed the level of creatine kinase MB (CK-MB), creatine kinase (CK) and troponin I (Tnl). SM treated rats significantly (P < 0.001) repressed the tissue factor (TF), thromboxane B2 (TXB2), plasminogen activator inhibitor 1 (PAI-1) and plasma fibrinogen (Fbg) and inflammatory cytokines and inflammatory mediators.ConclusionOur result clearly indicated that SM plays anti-arrhythmia effect in I/R injury in the rats via alteration of oxidative stress and inflammatory reaction. 相似文献
98.
99.
Marta López-Fauqued Laura Campora Frédérique Delannois Mohamed El Idrissi Lidia Oostvogels Ferdinandus J. De Looze Javier Diez-Domingo Thomas C. Heineman Himal Lal Janet E. McElhaney Shelly A. McNeil Wilfred Yeo Fernanda Tavares-Da-Silva 《Vaccine》2019,37(18):2482-2493
Background
The ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials showed that the adjuvanted recombinant zoster vaccine (RZV) was ≥90% efficacious in preventing herpes zoster in adults. Here we present a comprehensive overview of the safety data from these studies.Methods
Adults aged ≥50 (ZOE-50) and ≥70 (ZOE-70) years were randomly vaccinated with RZV or placebo. Safety analyses were performed on the pooled total vaccinated cohort, consisting of participants receiving at least one dose of RZV or placebo. Solicited and unsolicited adverse events (AEs) were collected for 7 and 30?days after each vaccination, respectively. Serious AEs (SAEs) were collected from the first vaccination until 12?months post-last dose. Fatal AEs, vaccination-related SAEs, and potential immune-mediated diseases (pIMDs) were collected during the entire study period.Results
Safety was evaluated in 14,645 RZV and 14,660 placebo recipients. More RZV than placebo recipients reported unsolicited AEs (50.5% versus 32.0%); the difference was driven by transient injection site and solicited systemic reactions that were generally seen in the first week post-vaccination. The occurrence of overall SAEs (RZV: 10.1%; Placebo: 10.4%), fatal AEs (RZV: 4.3%; Placebo: 4.6%), and pIMDs (RZV: 1.2%; Placebo: 1.4%) was balanced between groups. The occurrence of possible exacerbations of pIMDs was rare and similar between groups. Overall, except for the expected local and systemic symptoms, the safety results were comparable between the RZV and Placebo groups irrespective of participant age, gender, or race.Conclusions
No safety concerns arose, supporting the favorable benefit-risk profile of RZV. 相似文献100.